Abstract:
Radioactive arsenic (.sup.72 As) labelled tissue specific ligands are prepared and used in the medical imaging of malignant breast or prostate tumors.
Abstract:
Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.
Abstract:
Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.
Abstract:
Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance up-take of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.
Abstract:
Biomodulators can be administered together with an agent such as a drug or an imaging agent (specific or non-specific) structurally modified to take advantage of perturbations of cell oligosaccharide displays caused by biomodulators, to enhance images of a host, e.g., NMR-, X-ray- or radioimages, preferably by increasing aberrant tissue signal intensity. Biomodulators condition tissue to enhance or otherwise modify up-take of the drug or structurally modified imaging agent.
Abstract:
Radioactive arsenic (.sup.72 As) labelled tissue specific ligands are prepared and used in the medical imaging of malignant breast or prostate tumors.
Abstract:
Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.
Abstract:
Biomodulators, in conjunction with antibodies, tumor-specific agents or conjugates thereof, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radioimages, preferably by increasing aberrant tissue signal intensity.